AI Article Synopsis
- Monoclonal antibodies have significantly advanced personalized cancer treatment, but their size can hinder effective tumor targeting in some cases.
- Nanobodies, smaller and structurally distinct from monoclonal antibodies, are being explored as alternatives in cancer diagnostics and therapies.
- Current research highlights both clinical trials and preclinical developments of nanobodies, suggesting a promising future for their clinical application in oncology.
Article Abstract
Introduction: Monoclonal antibodies have revolutionized personalized medicine for cancer in recent decades. Despite their broad application in oncology, their large size and complexity may interfere with successful tumor targeting for certain applications of cancer diagnosis and therapy. Nanobodies have unique structural and pharmacological features compared to monoclonal antibodies and have successfully been used as complementary anti-cancer diagnostic and/or therapeutic tools.
Areas Covered: Here, an overview is given of the nanobody-based diagnostics and therapeutics that have been or are currently being tested in oncological clinical trials. Furthermore, preclinical developments, which are likely to be translated into the clinic in the near future, are highlighted.
Expert Opinion: Overall, the presented studies show the application potential of nanobodies in the field of oncology, making it likely that more nanobodies will be clinically approved in the upcoming future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13543784.2023.2249814 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!